golimumab

noun

go·​lim·​u·​mab gō-ˈlim-yü-ˌmab 

: a genetically engineered monoclonal antibody that inhibits the activity of tumor necrosis factor and is administered by subcutaneous injection to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis

Note: Golimumab is marketed under the trademark Simponi.